Information about in vitro toxicity early on during the drug discovery process support your internal decision making.
The available non-GLP in vitro toxicology assays are planned for cost-efficient screening with low compound consumption and cover the most commonly faced toxicity related challenges.
Service List
Cardiotoxicity Screening
Identify potential cardiac safety risks early with rapid hERG channel assays. Our fluorescence polarization assay provides IC50 values to detect hERG blockers, helping you de-risk compounds before advanced development. Full electrophysiology panels are available via our partner.
hERG Predictor Fluorescence Polarisation Assay
Screen compounds for hERG channel interactions using a fast, cost-efficient platform. The assay detects potential cardiotoxicity liabilities and delivers actionable IC50 data to support safety assessments.
Electrophysiology (via Our Partner Axxam)
Access comprehensive electrophysiology studies through our partner Axxam to evaluate cardiac ion channel safety. These assays complement early hERG screening with a broader cardiac safety profile.
Genotoxicity Screening
Evaluate mutagenic potential with MiniAMES, full AMES, and micronucleus assays (MNT). Our OECD-compliant studies detect chromosomal damage and point mutations, ensuring regulatory-ready genotoxicity data.
Cytotoxicity Screening
Measure cell viability and membrane integrity to assess general cytotoxicity. Using LDH release, ATP content, and other markers, our assays deliver EC50 values and actionable insights to guide dosing and study design.
Mechanistic Toxicity Assays
Uncover mechanisms behind cellular toxicity, including mitochondrial dysfunction, oxidative stress, and apoptosis. These assays provide mechanistic clarity to support risk assessment and compound optimization.
Hematologic Toxicity
Detect hemolytic potential with in vitro assays that measure erythrocyte disruption and hemoglobin release. Essential for assessing i.v. formulations and ensuring safety of both drugs and excipients.
Hepatoxicity and Drug Induced Liver Injury (DILI) Assessment
Identify hepatotoxicity risks early with our DILIscope package. Using high-content imaging and primary hepatocytes, we assess cell stress, steatosis, phospholipidosis, and lysosomal trapping to deliver sensitive, mechanistic insights into DILI risk.
